AllSci News
Adlai Nortye pushes CEACAM5-targeted Pan-RAS(ON) ADC into first-in-human trial
Adlai Nortye Biopharma, a Taiwan-based oncology company, has initiated a first-in-human clinical trial of AN4035, a bispecific antibody designed to target...
Oryzon secures US patent for LSD1 inhibitor vafidemstat in BPD
Oryzon Genomics (Madrid: ORY), the Barcelona-based epigenetics company, has secured a US Patent (No. 12,673,044) covering methods of treating non-aggressive symptoms of…
Genmab’s Tepkinly wins EC nod as first BsAb regimen for relapsed follicular lymphoma
The European Commission issued a marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R²) for relapsed or refractory follicular…
AstraZeneca, Ionis report Phase III failure for eplontersen in ATTR-CM
AstraZeneca (NYSE: AZN) and Ionis Pharmaceuticals (Nasdaq: IONS) reported that eplontersen (Wainua) failed to meet the primary endpoint of the...
Chemomab, Scipher merge in USD 150 million deal to advance AI-guided RA therapy
Israel-based Chemomab Therapeutics (Nasdaq: CMMB) and Burlington, Massachusetts-based Scipher Medicine Corporation have entered into a definitive merger...
CSPC’s B7-H3 ADC wins China breakthrough designation in platinum-resistant ovarian cancer
CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that SYS6043, a humanized monoclonal antibody-drug conjugate (ADC) targeting B7-H3, has been granted Breakthrough Therapy…
Emmecell’s cell therapy wins FDA fast-track designation for corneal endothelial disease
California-based Emmecell announced receipt of US FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002, its investigational allogeneic cultured human corneal endothelial…
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S
Washington, DC-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US FDA has granted Rare Pediatric Disease Designation (RPDD) to VCA-894A, an…
Ohio State University develops exosome-based RNA nanotechnology to silence mutant KRAS in mCRC
Ohio State University has received a USD 1.43 million NCI R01 grant to develop an exosome-based RNA nanotechnology platform targeting mutant KRAS in...
FDA grants accelerated approval to Vera’s Trutakna, first dual BAFF/APRIL inhibitor for IgA nephropathy
The US FDA has granted accelerated approval to Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk…
OTR Therapeutics partners with LG Chem to channel Chinese oncology assets into global development
Shanghai-based OTR Therapeutics and South Korea-based LG Chem (KRX: 051910) have announced a multi-program strategic collaboration to identify, evaluate, and advance oncology…
Seres' biotherapeutic resolves checkpoint inhibitor colitis without systemic immunosuppression
Cambridge, Massachusetts-based Seres Therapeutics (Nasdaq: MCRB) reported early clinical data suggesting that SER-155, its oral live biotherapeutic, may...
UroGen's UGN-501 oncolytic virus gains FDA clearance for non-muscle invasive bladder cancer trial
UroGen Pharma (Nasdaq: URGN) announced on July 8, 2026 that the US FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus...
Rejuvenation Technologies backed with grant to move TERT mRNA into clinic for alcoholic hepatitis
Rejuvenation Technologies, Inc., a Mountain View, California-based biotechnology company, has received a USD 2.06 million NIAAA SBIR Commercialization...
Immunome advances varegacestat toward approval as second oral option for desmoid tumors
The US FDA has accepted for review the New Drug Application submitted by Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) for varegacestat (formerly...
The AllSci Brief
Free, systematic R&D and deal news. Daily.